Insights

Beyond THC: Why Personalised Prescribing Matters in Medical Cannabis

For years the medical cannabis conversation has fixated on THC percentage. But higher potency does not mean better outcomes. Here is why personalised, evidence-led prescribing, not the number on the label, is shaping the future of treatment in the UK.
Cantourage UK
July 17, 2026

For years, discussions around medical cannabis have often centred on a single number: THC percentage.

Higher THC is frequently perceived as a marker of greater effectiveness, influencing how products are compared and, in some cases, how treatment options are viewed.

Yet this perspective oversimplifies what is, in reality, a complex clinical decision.

Medical cannabis is not prescribed according to the highest cannabinoid concentration. It is prescribed according to the needs of the individual patient. As the UK medical cannabis sector continues to mature, the conversation must move beyond potency alone and towards a more sophisticated understanding of personalised prescribing, clinical evidence and patient-centred care.

For healthcare professionals, pharmacies and industry partners alike, the future of medical cannabis will not be defined by stronger products. It will be defined by smarter prescribing.

Key Takeaways

Why THC Became the Focus

THC (tetrahydrocannabinol) is one of the primary cannabinoids found in cannabis and is often the first metric patients, retailers and even parts of the wider industry notice when comparing products.

This emphasis has, in part, been inherited from non-medical cannabis markets, where potency is frequently used as a proxy for product quality.

Healthcare operates differently.

In medicine, clinicians rarely select treatments based solely on the highest available strength. Instead, prescribing decisions balance efficacy, safety, tolerability and the individual needs of each patient.

Cannabis-based medicines should be approached in the same way.

Medical Cannabis Is Personalised Medicine

One of the defining characteristics of medical cannabis is that treatment is highly individualised.

Patients presenting with the same diagnosis may experience very different symptoms, have different treatment histories and respond differently to cannabinoid medicines.

For this reason, prescribing should never rely on THC percentage alone.

Instead, clinicians develop treatment plans based on a comprehensive clinical assessment that considers the patient's overall health, previous therapies and therapeutic objectives.

This approach reflects the broader principles of personalised medicine, where treatment decisions are tailored to the individual rather than the condition alone.

Beyond THC: What Clinicians Consider

THC concentration remains an important consideration, but it is only one part of the prescribing process.

Clinical decision-making may also include:

Patient Presentation

The nature and severity of symptoms remain central to treatment planning.

Medical History

Comorbidities and previous treatment outcomes help determine whether medical cannabis may be an appropriate option.

Current Medications

Potential interactions with existing medicines are carefully considered before prescribing.

Previous Cannabis Experience

Prior exposure to cannabis, whether prescribed or otherwise, may help inform treatment planning and dosing strategies.

Treatment Goals

Patients may have different therapeutic priorities depending on their condition, lifestyle and individual circumstances.

Tolerability

Prescribing decisions should balance potential benefits alongside the patient's ability to tolerate treatment over time.

THC Isn't the Whole Story

Modern cannabis-based medicines are complex therapeutic products.

Alongside THC, clinicians may also consider several other characteristics when selecting an appropriate treatment.

CBD Content

CBD may play an important role within certain treatment plans and is assessed alongside THC rather than independently.

Product Formulation

Whether a medicine is prescribed as a flower, oil or another licensed formulation can influence prescribing decisions and patient suitability.

Terpene Profile

Terpenes contribute to the overall composition of cannabis-based medicines. While research continues to evolve, clinicians increasingly consider the complete profile of a product rather than focusing solely on cannabinoid percentages.

Timing and Dosing Strategy

When and how a medicine is used may be just as important as the cannabinoid concentration itself.

Previous Response

Understanding how a patient has previously responded to treatment helps inform future prescribing decisions and supports continuity of care.

From Product-Led Thinking to Patient-Centred Prescribing

As the UK medical cannabis sector evolves, the conversation is gradually shifting.

Rather than asking: "Which product has the highest THC?"

Healthcare professionals are increasingly asking: "Which medicine is most appropriate for this patient?"

This represents an important step in the maturation of the sector.

It reflects a move away from product-led decision-making towards evidence-led, patient-centred prescribing.

Ultimately, success should not be measured by cannabinoid percentages but by whether patients receive treatment that is appropriate for their clinical needs and supported by ongoing care.

The Future of Medical Cannabis in the UK

The continued growth of medical cannabis depends on more than expanding product availability.

It requires continued investment in:

As prescribing becomes increasingly sophisticated, personalised medicine will play an ever-greater role in determining how cannabinoid medicines are used across UK healthcare.

What This Means for the Industry

For cultivators, manufacturers and distributors, this evolution presents an opportunity.

Success will increasingly depend not only on developing high-quality products but also on supporting clinicians with reliable supply, transparent product information and robust clinical evidence.

For healthcare providers, it reinforces the importance of placing patients, not products, at the centre of prescribing decisions.

The organisations that help build trust, consistency and clinical confidence will be the ones that shape the next chapter of medical cannabis.

Frequently Asked Questions

Does higher THC mean a better medical cannabis product?

No. THC concentration is only one factor considered during prescribing. Treatment decisions should always reflect the individual patient's clinical needs rather than potency alone.

Why is personalised prescribing important in medical cannabis?

Patients respond differently to treatment. Personalised prescribing allows clinicians to consider symptoms, medical history, treatment goals and previous responses when selecting an appropriate medicine.

What factors influence medical cannabis prescribing?

Prescribing decisions may consider THC and CBD content, product formulation, terpene profile, current medications, previous cannabis experience, treatment goals and overall clinical presentation.

Why is the medical cannabis industry moving beyond THC?

As clinical evidence grows, there is increasing recognition that successful treatment depends on selecting the right medicine for the right patient rather than simply choosing the highest THC concentration.

Conclusion

The future of medical cannabis will not be defined by potency alone.

It will be defined by evidence, consistency and personalised prescribing.

Moving beyond THC allows the industry to focus on what matters most: delivering safe, effective and patient-centred care supported by high-quality medicines and informed clinical decision-making.

At Cantourage, we believe the next phase of medical cannabis is built on collaboration across the healthcare ecosystem. By supporting clinicians, pharmacies and healthcare providers with access to high-quality cannabis-based medicines, we are helping advance a more mature, evidence-led and patient-centred approach to prescribing, because better outcomes come from treating the patient, not the percentage.